The page could not be loaded. The CMS.gov Web site currently does not fully support browsers with
Ethylenediamine-Tetra-Acetic (EDTA) Chelation Therapy for Treatment of Atherosclerosis
This is a longstanding national coverage determination. The effective date of this version has not been posted.
The use of EDTA as a chelating agent to treat atherosclerosis, arteriosclerosis, calcinosis, or similar generalized condition not listed by the FDA as an approved use is not covered. Any such use of EDTA is considered experimental.